期刊文献+

p53在乳腺癌中的表达及其临床意义 被引量:2

原文传递
导出
摘要 目的研究乳腺癌组织中p53蛋白的表达,探讨其表达结果与临床病理学指标的关系。方法以120例经病理医师确诊为乳腺癌的活性标本为研究对象,术前均未做任何放疗和化疗,诊断明确,临床资料完整,所有患者均行乳腺癌改良根治术,Ⅰ期51例,Ⅱ期41例,Ⅲ期28例;肿瘤直径1~10cm,<2cm者31例,≥2cm者89例;有腋窝淋巴结转移63例,无淋巴结转移57例。应用免疫组织化学SP法检测乳腺癌活性标本中p53的表达。结果 120例乳腺癌中,p53蛋白的阳性表达率为80.0%(96/120),其表达在乳腺癌不同临床分期、有无淋巴结转移上有显著差异(P均<0.05),而不同肿瘤大小其p53蛋白表达水平差异无统计学意义(P>0.05)。结论 p53蛋白表达与乳腺癌转移有关,是乳腺癌患者预后差的指标,检测p53对乳腺癌患者的预后判断和治疗有指导价值。
出处 《中国临床研究》 CAS 2011年第12期1108-1109,共2页 Chinese Journal of Clinical Research
  • 相关文献

参考文献8

  • 1Tavassoli FA.乳腺及女性生殖器官肿瘤病理学和遗传学[M].程虹等译.北京:人民卫生出版社,2006.312.
  • 2陈红秋,边建民.乳腺癌雌孕激素受体临床病理研究进展[J].广西医学,2003,25(2):220-221. 被引量:16
  • 3lwamb P, Crawford L. Characterization of the human p53 gene [J].Mol cell Biol, 1986,6 (5) : 1379 - 1385.
  • 4Iwaya K,Tsuda H, Hiraide H, et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer[J]. Jpn J Cancer Res, 1991,82(7) :834 -840.
  • 5罗文伟,任建强.C-erb B-2、P53、ER、PR在乳腺癌中的表达和临床意义[J].医学信息,2011,24(12):3743-3744. 被引量:6
  • 6黄自明,赵倩倩,李杰.乳腺癌组织中C-erbB-2,p53,ER和PR的表达及临床意义[J].中华实用诊断与治疗杂志,2011,25(7):636-637. 被引量:18
  • 7Bidard FC,Matthieu MC,Chollet P,et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes[J]. Ann Onco1,2008,19 ( 7 ) : 1261 - 1265.
  • 8Menezes MV, Cestarl AL, Almeida O, et al. Protein expression of C- erbB-2 and p53 in normal ducts,ductal carcinoma in situ and invasive carcinoma of the same breast[J]. Sao Paulo Med J ,2006,124 (3) :121 -124.

二级参考文献22

  • 1宋旭东,王献华,张素华,郑素芹,李琪佳,向巨才.158例乳腺癌雌孕激素受体表达分析[J].华北煤炭医学院学报,1999,1(6):503-504. 被引量:1
  • 2黄玉钿,郑曦,黄双月,吴钦穗,成辉.乳腺癌P53、CA153的表达及意义[J].中国实验诊断学,2005,9(2):221-224. 被引量:15
  • 3王崇宇,杨苏敏,原学斌,刘苗生,张淑玲.乳腺癌雌激素与孕激素受体的表达及其临床意义[J].长治医学院学报,1995,9(3):191-193. 被引量:1
  • 4吴祥德 董守义.乳腺疾病诊治:第1版[M].北京:人民卫生出版社,1996.326-327.
  • 5Allred DC JM,Berardo M,et al.Prognosis and predictive factors in breast cancer by immunohistochemical analysis[J].Mod Pathol,1998,11:155-168.
  • 6Chambers AF,Matrisian LM.Changing Views of the roles of matrix metalloproteinase in matastasis[J].J Nafi Cancer Znst,1997,89:1260.
  • 7Lamb P,Grawford L.Characterization of the P53 gene[J].Mol cell Biol,1986,6(5):1379.
  • 8Lawya K,Tsuda H,Hiraide H,et al.Nuclear P53 immunoreaction Assoclated with poor prognisis of breast cancer[J].J pn cancer Res,1991,82(7):834-840.
  • 9Henderson T O, Amsterdam A, Bhatia S, et al. Systermatic review: surveillance for breast cancer in women treated with chest radiation for childhood adolescent, or young adult cancer [J]. Ann Intern Med,2010,152(7):444-455.
  • 10Kulka J, Tokes A M, Toth A I. Immunohistochemical phenotype of breast carcinoma predicts the effectiveness of primary systemic therapy[J]. Magy Onko1,2009,53(4):335-343.

共引文献92

同被引文献28

  • 1李宝江,朱志华,王军业,侯景辉,赵进明,张蓬原,姚广裕,王曦,龙浩,杨名添,戎铁.Ki67、P53、VEGF和C-erbB-2在乳腺癌组织中表达的相关性研究及其临床意义[J].癌症,2004,23(10):1176-1179. 被引量:126
  • 2王黎明,徐世文,龚晓萌.cerbB-2、Bcl-2、Ki-67在乳腺癌中的表达及临床意义[J].现代肿瘤医学,2006,14(10):1217-1219. 被引量:4
  • 3刘华,施威,吴德敬.乳腺癌组织p53、bcl-2、PCNA和雌激素水平与临床病理及预后的关系[J].临床肿瘤学杂志,2006,11(12):898-900. 被引量:6
  • 4Jemal A, Bray F, Center MM, et al. Golbal cancer statistic [ J ]. CA Cancer J Clin,2011,61 (2) :69 -90.
  • 5Rajangam T, An SS. Fibrinogen and fibrin based micro and nano scaffolds incorporated with drugs, proteins, cells and genes for ther- apeutic biomedical applications [ J ]. Int J Nanomed, 2013,8 : 3641 - 3662.
  • 6Kolodziejczyk J, Ponczek MB. The role of fibrinogen, fibrin and fi- brin(ogen) degradation products(FDPs) in tumor progression [ J]. Contemp Oncol (Pozn) ,2013,17 (2) : 113 - 119.
  • 7Suzuki Y, Isemura M. Binding interaction between ( - ) - epigallo- catechin gallate causes impaired spreading of cancer cells on fibrin- ogen[J]. Biomed Res,2013,34(6) :301 -308.
  • 8Rybarczyk B J, Simpson - Haidaris PJ. Fibrinogen assembly, secre- tion,and deposition into extracellular matrix by MCF -7 human breast carcinoma cells [ J ]. Cancer Res, 2000, 60 ( 7 ) : 2033 - 2039.
  • 9Garcia del Muro X,Condom E,Vigurs F,et al. p53 and p21 Ex- pression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined - modality approach [ JJ. Cancer ,2004,100 ( 9 ) : 1859 - 1867.
  • 10Hirano H,Tsuji M,Kizaki T ,et al. Expression of matrix metallopro- teinases,tissue inhibitors of metalloproteinase, collagens, and Ki67 antigen in pleural malignant mesothelioma:An immunohistochemi- cal and electron microscopic study [ J ]. Med Electron Microsc, 2002,35 ( 1 ) : 16 - 23.

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部